middle.news
Entropy Neurodynamics Posts 50% Remission in BED Trial and Expands IBS Patent Portfolio
8:26am on Wednesday 22nd of July, 2026 AEST
•
Biotechnology
Read Story
Entropy Neurodynamics Posts 50% Remission in BED Trial and Expands IBS Patent Portfolio
8:26am on Wednesday 22nd of July, 2026 AEST
Key Points
50% clinical remission in Phase 2 BED trial cohort 1
100% clinically meaningful response rate achieved
75% response rate in Phase 2a IBS trial
New US provisional patent filed for IBS therapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Entropy Neurodynamics (ASX:ENP)
OPEN ARTICLE